Forsteo ® (teriparatid)

För fullständig produktresumé för Forsteo® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Forsteo® (teriparatid): Användning med vacciner mot covid-19

Användning av vacciner mot SARS-CoV-2 på patienter som injicerats med teriparatid [rDNA-ursprung] har inte studerats.

Administration of COVID-19 Vaccines to Patients Receiving Teriparatide

Severe acute respiratory syndrome coronavirus 2 is an emerging virus that has caused the recent COVID-19 pandemic.1 Recently, vaccines have been developed against SARS-CoV-2 and additional vaccines are expected to be available in the coming months.2

SARS-CoV-2 Vaccination With Teriparatide

The use of a SARS-CoV-2 vaccine in patients treated with teriparatide has not been studied by Lilly.

Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with teriparatide should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient as well as the risks and benefits of vaccination. Consultation with an infectious disease expert may be helpful in high-risk or emergency situations such as the current COVID-19 pandemic.

Vaccination Against COVID-19 Treatment Guidance in Patients With Osteoporosis

Recommendations for the management of patients with osteoporosis in relation to COVID-19 vaccination have been published by the International Osteoporosis Foundation.3

For the most current information please refer to Joint Guidance on COVID-19 Vaccination and Osteoporosis Management.3

 

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to

References

1. Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y

2. Su Z, Wen J, McDonnell D, et al. Vaccines are not yet a silver bullet: the imperative of continued communication about the importance of COVID-19 safety measures. Brain Behav Immun Health. 2021;12:100204. https://doi.org/10.1016/j.bbih.2021.100204

3. Joint Guidance on COVID-19 Vaccination and Osteoporosis Management. The International Osteoporosis Foundation. March 9, 2021. Accessed March 26, 2021. https://www.osteoporosis.foundation/news/joint-guidance-covid-19-vaccination-and-osteoporosis-management-20210309-1500

4. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 26, 2021. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19

5. COVID-19. European Centre for Disease Prevention and Control. Accessed March 26, 2021. https://www.ecdc.europa.eu/en/novel-coronavirus-china

Glossary

COVID-19 = coronavirus disease 2019

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

EU WHO = World Health Organization (European regional office)

ECDC = European Centre for Disease Prevention and Control

Datum fӧr senaste ӧversyn January 11, 2021


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss